CBA Frontier Insights · Daily44 issues
All back issues
October 2026
17SatDaily 2026-10-1742 events16FriEMA Backs Oral RAS Inhibitor Rasonque for Metastatic Pancreatic Cancer43 events
15ThuFDA Approves First Therapy for BCG-Unresponsive Papillary-Only Bladder Cancer40 events14WedIvonescimab Beats Pembrolizumab on Overall Survival in Frontline PD-L1-Positive Lung Cancer43 events
13TueBMS RayzeBio Bet Pays Off With First Phase 3 Alpha Radiopharmaceutical Win38 events12MonNovartis Licenses Abogen mRNA T Cell Engager for $575 Million Upfront25 events
11SunIberdomide Combination Halves Progression Risk in Relapsed Myeloma23 events10SatTwo B7-H3 ADCs Post Identical 0.46 Survival Hazard Ratios in Relapsed Small Cell Lung Cancer34 events
09FriFDA Approves Atezolizumab Plus Chemotherapy for Stage III Mismatch Repair Deficient Colon Cancer35 events08ThuFDA Approves Tucatinib Regimen for HER2-Positive Breast Cancer Maintenance42 events
07WedEpkinly Cuts Progression Risk 51% in First-Line DLBCL, Setting New Standard42 events06TueNobel Prize in Medicine Goes to Optogenetics Pioneers54 events
05MonRetatrutide Delivers 20.8% Weight Loss at 80 Weeks in TRIUMPH-2 Topline18 events04SunWeekly Oral Islatravir-Lenacapavir Matches Daily HIV Regimen in Phase 324 events
September 2026
30WedAstraZeneca Puts $2 Billion Into Summit, Anchoring Ivonescimab Alliance37 events29TueIvonescimab Becomes First Drug to Beat Pembrolizumab on Overall Survival in Lung Cancer41 events
28MonMulti-omic atlas maps gene regulation across 21 human tissues4 events27SunFDA Approves AbbVie's Tavapadon for Parkinson's Disease8 events
26SatCagriSema Outperforms Tirzepatide Head-to-Head in REIMAGINE 5 Obesity Showdown29 events25FriFDA advisors back Grail's Galleri multi-cancer blood test despite efficacy doubts33 events
24ThuRoche-Ionis Sefaxersen Succeeds in Phase 3 IgA Nephropathy, Setting Up Novartis Showdown28 events23WedCagriSema Beats Tirzepatide Head-to-Head and Clears Second Phase III Obesity Test29 events
22TueGalleri's 140,000-Person Trial Fails to Cut Late-Stage Cancers27 events21MonIvonescimab Posts 16.9-Month PFS After Third-Generation EGFR-TKI Failure in NSCLC13 events
20SunIvonescimab Beats Pembrolizumab on Overall Survival in PD-L1-Positive NSCLC7 events19SatIvonescimab First to Beat Pembrolizumab on Overall Survival in Phase 3 Lung Cancer26 events
18FriFDA Approves First-Ever Gene Therapy for Children with Sanfilippo Syndrome Type A24 events16WedGotistobart Nearly Doubles Median Overall Survival in Pretreated Squamous NSCLC35 events
15TueIvonescimab Extends Overall Survival Over Pembrolizumab in First-Line PD-L1-Positive NSCLC35 events14MonIvonescimab Beats Pembrolizumab on Overall Survival in Front-line PD-L1-positive NSCLC8 events
13SunObinutuzumab Beats Tacrolimus in Phase 3 Membranous Nephropathy Trial18 events12SatFDA Grants Priority Review to First In Vivo CRISPR Therapy for Hereditary Angioedema35 events
11FriFDA Approves Moderna's mFlusiva, First mRNA Seasonal Flu Vaccine25 events10ThuIvonescimab Cuts Death Risk 27% Versus Keytruda in Frontline Lung Cancer28 events
09WedGene-Edidted Pig Kidney Sustains Dialysis-Free Patient for 271 Days Before Successful Human Transplant30 events07MonRoivant's Inhaled Mosliciguat Posts 56% PVR Reduction in Phase 2 PH-ILD Win17 events
06SunNovartis Pelacarsen Cuts Lp(a) but Misses on Cardiovascular Events in Phase 315 events05SatIvonescimab Becomes First Bispecific to Beat Pembrolizumab on Overall Survival31 events